APOE and dementia: This combination trial bridges the gap between pharmacological and non-pharmacological strategies for dementia prevention and uses a novel precision prevention approach, as it targets an APOE-ε4 enriched population of 600 older adults (60–79 years) at increased risk of dementia, identified via assessment of vascular risk factors and cognitive screening [11,22].